Figure 9
The Spag6-deficient (KO) MEFs are more sensitive to paclitaxel.
Cell viability assay. Immortalized (left) and passage two (right) MEFs were treated with increasing concentrations of paclitaxel for 48 hr and cell viability was measured. Notice that compared to the wild-type MEFs, viability is significantly lower in the Spag6-deficient MEFs when treated with 100 and 1000 nM of paclitaxel in both immortalized and passage two MEFs. *p < 0.05.
